Citadel Advisors
ZVRA icon

Citadel Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Citadel Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Sell
12,167
-614,532
-98% -$6.83M ﹤0.01% 12214
2026
Q1 		$5.84M Sell
626,699
-216,155
-26% -$1.95M ﹤0.01% 4088
2025
Q4 		$7.55M Buy
842,854
+651,058
+339% +$6.16M ﹤0.01% 3649
2025
Q3 		$1.82M Buy
191,796
+77,529
+68% +$778K ﹤0.01% 6262
2025
Q2 		$1.01M Sell
114,267
-134,565
-54% -$1.09M ﹤0.01% 7067
2025
Q1 		$1.86M Buy
248,832
+246,343
+9,897% +$1.96M ﹤0.01% 5661
2024
Q4 		$20.8K Sell
2,489
-65,420
-96% -$558K ﹤0.01% 13163
2024
Q3 		$471K Sell
67,909
-37,329
-35% -$253K ﹤0.01% 8388
2024
Q2 		$516K Buy
105,238
+104,913
+32,281% +$497K ﹤0.01% 7977
2024
Q1 		$1.89K Sell
325
-334,452
-100% -$2.06M ﹤0.01% 14075
2023
Q4 		$2.19M Buy
334,777
+167,107
+100% +$782K ﹤0.01% 5200
2023
Q3 		$808K Buy
167,670
+139,229
+490% +$695K ﹤0.01% 7015
2023
Q2 		$145K Sell
28,441
-2,745
-9% -$14.8K ﹤0.01% 10390
2023
Q1 		$172K Sell
31,186
-77,674
-71% -$411K ﹤0.01% 10428
2022
Q4 		$500K Buy
+108,860
New +$553K ﹤0.01% 8238
2022
Q1 		– Sell
-23,813
Closed -$152K – 14740
2021
Q4 		$207K Sell
23,813
-5,165
-18% -$46.1K ﹤0.01% 11781
2021
Q3 		$270K Buy
28,978
+812
+3% +$8.19K ﹤0.01% 11300
2021
Q2 		$361K Sell
28,166
-129,305
-82% -$1.39M ﹤0.01% 10822
2021
Q1 		$1.45M Buy
+157,471
New +$1.38M ﹤0.01% 7194
2020
Q1 		– Sell
-2,606
Closed -$16K – 10298
2019
Q4 		$16K Buy
+2,606
New +$20.7K ﹤0.01% 8968

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's ZVRA Position: Q2 2026 in Review

Citadel Advisors reduced its Zevra Therapeutics (ZVRA) stake by 98% in Q2 2026, selling an estimated $6.83M and leaving 12,167 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #12214.

Citadel Advisors first reported a position in ZVRA in Q4 2019 and has held it in 20 quarters since. The position peaked at $7.55M in Q4 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Citadel Advisors held 12,167 shares of Zevra Therapeutics worth $174K as of Q2 2026.
  • Citadel Advisors sold 614,532 Zevra Therapeutics shares in Q2 2026, an estimated $6.83M.
  • Zevra Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12214 holding.
  • Citadel Advisors first reported a position in Zevra Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • Citadel Advisors's Zevra Therapeutics position peaked at $7.55M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.